Advertisement
United States  

“News neutrality by unbiased coverage”
One News Page
> >

Medicine Man Technologies Reports Record Quarterly Operating Revenue of $4.6M, Quarterly Investment Related Income of $2.6M, and its Third Consecutive Quarter Profit Posting of $4.9M

Accesswire Thursday, 8 November 2018 ()
Medicine Man Technologies Reports Record Quarterly Operating Revenue of $4.6M, Quarterly Investment Related Income of $2.6M, and its Third Consecutive Quarter Profit Posting of $4.9M*DENVER, CO / ACCESSWIRE / November 8, 2018 / *Medicine Man Technologies Inc. (OTCQB: MDCL) ("Medicine Man Technologies" or "Company"), one of the United States' leading cannabis branding and consulting companies today provided financial results for the quarter ended September 30, 2018.

During the three months ending September 30, 2018, the Company generated operating revenues of $4,647,163, an increase of approximately 400% as compared to revenues of $928,264 in the three months ending September 30, 2017. Other income for the three months ending September 30, 2018 increased to $2,605,672 as compared with losses in the three months ending September 30,2017 of . This substantial increase in the Company's overall revenue stream is related to both internal revenue source growth as well as the Company's Canada House Wellness (CHV) Master Licensing Agreement as announced in July of this year.

The Company reported cost of goods and services totaling $459,280 during the three months ended September 30, 2018. This is compared to $297,185 during the same time period in 2017. The increase is primarily due to an increase in overall product sales volume.

Operating expenses during the three months ended September 30, 2018, increased by $892,051 to $1,824,876 over the prior period of $950,825, ended September 30, 2017 noting $673,500 of this expense increase was related to stock compensation.

The Company reported net income related to the three months ending September 30, 2018 of $4,950,679 or $0.18 per share as compared with losses of as related to the three months ending September 30, 2017.

Year to date total income performance increased dramatically to $9,917,476 for the nine months ending September 30, 2018 as compared to total income of $2,585,479 as reported for the nine months ending September 30, 2017.

Year to date net income performance increased dramatically to $5,157,717 or $0.19 per share for the nine months ending September 30, 2018 as compared to losses of or per share as reported for the period ending September 30, 2017.

While the Company continues to grow its organic revenues, the Master Licensing Agreement as noted was responsible for a large portion of this revenue growth however, organic growth still increased to $3,782,921 in the nine months ended September 30, 2018 from $2,485,479 as related to the nine months ended September 30, 2017.

"We continue to prove out our path to profitability model and demonstrate strong organic as well as one-time revenue growth as we conclude our third consecutive profitable quarter, followed closely by achieving our seventh quarter of consecutive revenue growth," Brett Roper, Medicine Man Technologies' co-founder, and CEO stated. "We are also exploring other globally sourced master license agreement opportunities and are pleased to also acknowledge our Company's move to QX status on the OTC markets as achieved this past September."

Joshua Haupt, Medicine Man Technologies Chief Operating Officer added, "With this exceptional progress and the lack of any debt, I am very excited about what our future holds as we move into 2019. With our Grow Ohio Pharma client's Zanesville Ohio facility coming online coupled with our Calypso client's Erie Pennsylvania facility planned for operational status in the second quarter of 2019, we have many new opportunities ahead for the Company. I also look forward to attending next week's MJ Business Conference in Las Vegas Nevada and connecting with my many colleagues in the industry."

Andy Williams, Medicine Man Technologies' Chairperson of the Board stated, "With the Colorado Governorship going to Jared Polis, a seasoned advocate of the cannabis industry and states' rights this provides new momentum for the continuation of the industry's success which has continued to bolster the state's economy, generating record-setting revenue and creating thousands of jobs for the citizens of Colorado. As a result of regulatory advancements made by legislative bodies on the local, federal and international levels, the national cannabis market place continues to expand as further evidenced by this week's election cycle. Medicine Man Technologies' multi-jurisdictional business model has positioned the Company to leverage this dramatic growth nationally setting a clear path to Colorado based public company ownership in 2019."

*Conference Call Instructions*

The Company will host a conference call on Friday, November 9, 2018 at 10:30 AM Eastern Time to discuss the results.

*Participant Dial-In Numbers:*

*TOLL-FREE 1-* *877-407-9716*

*TOLL/INTERNATIONAL 1-201-493-6779*

*Participants should request the Medicine Man earnings call or provide confirmation code 13684963.*

Investors are invited to listen via webcast available on the Medicine Man Technologies investor section of the Company's website at http://www.medicinemantechnologies.com/investor-calendar.html. Please visit the website 15 minutes prior to the call to register, download, and install any necessary audio software. For interested individuals unable to join the conference call, a replay of the call will be available through November 23, 2018, at 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 13684963. The online archive of the webcast will be available on the investor section of the Company's website for 30 days following the call.

Brett Roper, Co-Founder and Chief Executive Officer of Medicine Man Technologies, and Jonathan Sandberg, Chief Financial Officer, will be answering shareholder questions at the conclusion of the call. Should you have questions prior to the conference call please send an email to MDCL@kcsa.com with 'MDCL Question' in the subject line. Management will answer as many questions as time will allow.

*About Medicine Man Technologies, Inc.*

Established in March 2014, the Company secured its first client/licensee in April 2014. To date, the Company has provided guidance for several clients that have successfully secured licenses to operate cannabis businesses within their state. The Company currently has or has had active clients in California, Iowa, Oregon, Colorado, Nevada, Illinois, Michigan, Oklahoma, Missouri, Arkansas, Pennsylvania, Florida, Ohio, Maryland, New York, Massachusetts, Puerto Rico, Canada, Australia, Germany, and South Africa. We continue to focus on working with clients to 1) utilize its experience, technology, and training to help secure a license in states with newly emerging regulations, 2) deploy the Company's highly effective variable capacity constant harvest cultivation practices through its deployment of Cultivation MAX, and eliminate the liability of single grower dependence, 3) avoid the costly mistakes generally made in start-up, 4) stay engaged with an ever expanding team of licensees and partners, all focused on quality and safety that will "share" the ever-improving experience and knowledge of the network, and 5) continuing the expansion of our Brands Warehouse concept through entry into industry based cooperative agreements and pursuing other acquisitions as they prove suitable to our overall business development strategy.

*Safe Harbor Statement*

This press release may contain forward-looking statements which are based on current expectations, forecasts, and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues and any payment of dividends on our common and preferred stock, statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the Securities and Exchange Commission. Among other matters, the Medicine Man Technologies may not be able to sustain growth or achieve profitability based on many factors including, but not limited to, general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC filings. We have incurred and will continue to incur significant expenses in the expansion of our existing and new service lines, noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long-term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations where we will be providing services, the impact of which cannot be predicted at this time.

To be added to the Medicine Man email distribution list, please email, MDCL@kcsa.com with MDCL in the subject line.

For more information, visit us at *www.medicinemantechnologies.com**;**www.threealight.com*

*Contact Information:*

Brett Roper via
info@medicinemantechnologies.com
Telephone (303) 371-0387

*MEDICINE MAN TECHNOLOGIES, INC.
CONSOLIDATED BALANCE SHEETS*
Expressed in U.S. Dollars *September 30, 2018* *December 31, 2017*


*Assets*
Current assets

Cash and cash equivalents
$ 529,674 $ 748,715
Accounts receivable
1,009,170 461,343
Accounts receivable - related party
53,839 25,719
Litigation receivable
990,864 -
Short-term note receivable, net of allowance
188,550 191,111
Inventory
441,960 106,091
Other assets
34,582 42,819
Total current assets
3,248,639 1,575,798


Non-current assets

Fixed assets, net accumulated depreciation of $131,405 and $82,038
$ 84,493 $ 150,047
Intangible assets, net accumulated amortization of $12,275 and $7,388
82,825 87,712
Goodwill
12,304,306 9,304,306
Investment
5,260,840 -
Other non-current assets
26,317 14,500
Total non-current assets
17,758,781 9,556,565


Total assets
$ 21,007,420 $ 11,132,363


*Liabilities and Stockholders' Equity*



Current liabilities

Accounts payable
$ 172,360 $ 123,251
Accounts payable - related party
53,000 155,177
Accrued expenses
47,684 -
Other liabilities
- 56,495
Total current liabilities
273,044 334,923


Long-term liabilities

Note payable - related party
$ - $ 58,280
Total long-term liabilities
- 58,280


Total liabilities
273,044 393,203


Commitments and contingencies, note 13

Shareholders' equity

Common stock $0.001 par value. 90,000,000 authorized, 27,578,310 and 22,991,137 were issued and outstanding September 30, 2018 and December 31, 2017, respectively
$ 28,766 $ 23,113
Additional paid-in capital
20,283,174 13,997,441
Additional paid-in capital - Warrants
2,054,369 3,508,256
Accumulated other comprehensive (loss)
- -
Retained earnings
(1,631,933 ) (6,789,650 )
Total shareholders' equity (deficit)
20,734,376 10,739,160


Total liabilities and stockholders' equity
$ 21,007,420 $ 11,132,363

*MEDICINE MAN TECHNOLOGIES, INC.
CONSOLIDATED STATEMENT OF COMPREHENSIVE (LOSS) AND INCOME *
For the Three and Nine Months Ended September 30, 2018 and 2017
Expressed in U.S. Dollars *Three Months Ended September 30,* *Nine Months Ended September 30,*

*2018* *2017* *2018* *2017*


*Operating revenues*

Product sales, net
$ 280,737 $ 278,495 $ 797,381 $ 506,900
Product sales - related party, net
143,761 61,768 425,499 184,711
Litigation revenue
180,000 - 1,015,154 -
Cultivation Max
88,933 - 304,090 -
Master licensing fees
3,518,322 - 3,518,322 -
Licensing fees
237,700 347,504 663,414 848,816
Consulting fees
163,147 238,480 486,747 805,086
Reimbursements
29,840 - 72,920 -
Services - related party
4,479 - 13,437 -
Seminars and others
244 2,017 4,279 6,239
Total revenue
4,647,163 928,264 7,301,243 2,351,752


*Cost of goods and services*

Cost of goods and services
$ 421,055 $ 282,894 $ 1,091,386 $ 694,018
Cost of goods and services - related party
38,225 14,291 121,808 40,327
Total cost of goods and services
459,280 297,185 1,213,194 734,345


*Gross profit*
$ 4,187,883 $ 631,079 $ 6,088,049 $ 1,617,407


*Operating expenses*

General and administrative
$ 170,117 $ 331,764 $ 417,467 $ 735,018
Professional services
177,103 144,796 657,694 384,278
Acquisition costs
- 42,600 - 141,301
Stock based compensation expenses
837,500 164,000 837,500 4,644,318
Officers and directors bonuses
145,104 90,823 196,157 90,823
Advertising
32,110 49,592 109,650 136,436
Conference and travel expenses
57,595 - 183,530 -
Salaries
423,347 127,250 1,144,567 220,365
Total operating expenses
$ 1,842,876 $ 950,825 $ 3,546,565 $ 6,352,539


*Income from operations*
$ 2,345,007 $ (319,746 ) $ 2,541,484 $ (4,735,132 )


*Other income/expense*

Interest (income)
$ (7,562 ) $ (7,562 ) $ (22,439 ) $ (22,439 )
Net loss on derivative liability
- 136,088 - 4,706
Interest expense related to convertible notes
- 22,636 - 66,965
Loss on sales of assets
- - 4,316 -
Loss on management fee contracts
- - - 70,257
Net loss on available for sale securities
- 14,719 - 14,457
Unrealized (gain)/loss on investments
(2,598,110 ) - (2,598,110 ) (219 )
Total other expense
(2,605,672 ) 165,881 (2,616,233 ) 133,727


*Net (loss) income*
$ 4,950,679 $ (485,627 ) $ 5,157,717 $ (4,868,859 )


*Earnings per share attributable to common shareholders:*

Basic and diluted (loss)/earnings per share
$ 0.18 $ (0.02 ) $ 0.19 $ (0.22 )
Weighted average number of shares outstanding - basic and diluted
27,578,310 21,883,853 27,578,310 21,883,853


Other comprehensive (loss), net of tax

Net unrealized (loss) on available for sale securities
- - - -
Total other comprehensive income (loss), net of tax
- - - -


*Comprehensive (loss) gain*
$ 4,950,679 $ (485,627 ) $ 5,157,717 $ (4,868,859 )

*MEDICINE MAN TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS*
For the Nine Months Ended September 30, 2018 and 2017
Expressed in U.S. Dollars *2018* *2017*
*Cash flows from operating activities*

Net income for the period
$ 5,157,717 $ (4,868,859 )
Adjustments to reconcile net income to net cash provided by operating activities

Loss (gain) on investment, net
- 4,706
Stock based compensation
837,500 4,644,318
Depreciation and amortization
54,253 43,650
Changes in operating assets and liabilities

Proceeds from note receivable
2,561 (22,439 )
Accounts receivable
(1,566,811 ) (373,902 )
Inventory
(335,869 ) (87,685 )
Other assets
(3,580 ) (65,331 )
Accounts payable and other liabilities
(61,879 ) 68,490
*Net cash earned (used) from operating activities*
4,083,892 (637,052 )


*Cash flows from investing activities*

Sale of assets
16,187 (242,685 )
Short term debt
(58,280 ) -
Acquisition investment
- 233,357
Investment proceeds
(5,260,840 ) -
AFS securities investment, net
- 4,305
*Net cash earned from investing activities*
(5,302,933 ) (5,023 )


*Cash flows from financing activities*

Sale of common stock
1,000,000 1,058,658
Cash raised by sale of convertible debt
- 179,777
*Net cash earned from financing activities*
1,000,000 1,238,435


Net decrease in cash and cash equivalents
(219,041 ) 576,360
Cash and cash equivalents - beginning of period
748,715 351,524
*Cash and cash equivalents - end of period*
$ 529,674 $ 927,884

*SOURCE:* Medicine Man Technologies Inc.
View source version on accesswire.com:
https://www.accesswire.com/527570/Medicine-Man-Technologies-Reports-Record-Quarterly-Operating-Revenue-of-46M-Quarterly-Investment-Related-Income-of-26M-and-its-Third-Consecutive-Quarter-Profit-Posting-of-49M
0
shares
ShareTweetSavePostSend
 

You Might Like


Recent related news from verified sources

CV Sciences logged strong CBD product sales in the third quarter

CV Sciences Inc (OTCMKTS:CVSI) announced Wednesday that it expanded CBD product sales sequentially by 10% to $13.6 million in the third quarter from $12.3...
Proactive Investors - Business

Tetraphase Pharmaceuticals reports lower 3Q results, but investors focus on US launch of Xerava

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) posted a loss in the third quarter and lower revenue, but the focus for investors is on the October launch of its...
Proactive Investors - Business

ShotSpotter beats Street's 3Q revenue estimate, but falls short on earnings forecast

ShotSpotter Inc (NASDAQ:SSTI) beat Wall Street’s estimates for third-quarter revenue and lifted its revenue forecast for the year, but missed the consensus...
Proactive Investors - BusinessAlso reported by •bizjournals

Cronos revenue nearly triples after Canada cannabis legalization, but swings to a loss for third quarter

Cronos Group (NASDAQ:Cron, TSX:Cron) saw revenue nearly triple to C$3.8 million in its latest quarter as the cannabis company took advantage of the legalization...
Proactive Investors - Business


Tweets about this


Other recent news in Press Releases

AIA Offers Resources for Recovery from CALIFORNIA WildfiresStanley Law Develops Custom SOFTWARE Program for Clients to Follow Case in Real Time
Satisfy Your Wanderlust This BLACK FRIDAY; EF Ultimate Break to Slash Travel Prices Up to 20% to Dream DestinationsLeading Reverse Pharmaceutical Distributor Hires On-Site Service Representative for NORTHERN CALIFORNIA
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2018 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Contact us  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest